查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949534

製藥生產軟體市場 - 全球產業規模、佔有率、趨勢、機會及預測（按軟體類型、部署模式、最終用戶、地區和競爭格局分類，2021-2031年）

Pharmaceutical Manufacturing Software Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Software Type, By Deployment Mode, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球製藥生產軟體市場預計將從 2025 年的 32.5 億美元成長到 2031 年的 51.4 億美元，複合年成長率為 7.94%。

此細分市場包含旨在管理、監控和簡化藥品生產工作流程，同時確保嚴格遵守監管要求的數位化系統。該市場的關鍵組成部分包括生產執行系統 (MES) 和企業品管系統 (EQMS)，它們有助於批次記錄的數位化，提高營運效率以維持良好生產規範 (GMP)，並最終為製造商提供貫穿整個產品生命週期的關鍵即時營運洞察和資料完整性。

市場概覽
預測期 2027-2031
市場規模：2025年 32.5億美元
市場規模：2031年 51.4億美元
複合年成長率：2026-2031年 7.94%
成長最快的細分市場 製造執行系統（MES）
最大的市場 北美洲

市場成長的主要驅動力是企業為滿足嚴格的監管合規要求和營運規範，透過更完善的流程控制來減少生產延誤。隨著企業努力消除人為錯誤並確保生產穩定，對自動化監控解決方案的依賴性顯著增強。包裝與加工技術協會 (PMMI) 預測，到 2024 年，83% 的製藥企業將把可靠性和可重複性作為其主要營運目標——而先進的自動化軟體恰好能夠滿足這一需求。然而，實施新系統所需的高昂資本成本以及嚴格的檢驗程序構成了重大障礙，可能會限制中小型製造商採用這些解決方案。

市場促進因素

隨著製藥企業整合網實整合系統以提高生產效率，醫藥4.0和智慧製造技術的快速普及正在從根本上重塑市場格局。這種數位轉型使工廠能夠利用物聯網感測器和進階分析技術來建立互聯生態系統，從而最佳化批次放行時間並減少停機時間。製造商正從孤立的舊有系統轉向支援預測性維護和自主決策的整合平台。根據羅克韋爾自動化於2024年3月發布的第九份年度智慧製造報告：生命科學版，96%的生命科學製造商表示他們正在實施或評估智慧製造技術，以提高敏捷性和競爭力。

同時，對即時品質保證和端到端供應鏈可追溯性的需求日益成長，迫使製造商升級其軟體基礎設施。監管機構正在實施更嚴格的序列化要求以打擊假藥，因此，一個能夠確保從原料採購到最終交貨的資料完整性和透明度的強大平台至關重要。根據斑馬技術公司 (Zebra Technologies) 於 2024 年 6 月發布的《2024 年醫藥供應鏈願景研究》，76% 的受訪患者希望製藥公司使用先進技術來確保藥品安全並檢驗其來源。為了滿足這些技術需求，在人手不足的情況下，製造商正在增加其數位化預算。根據美國全國製造商協會 (NAM) 於 2024 年 3 月發布的《2024 年第一季製造業展望調查》，65% 的行業領導者認為「難以吸引和留住優秀人才」是一項重大業務挑戰，這促使他們加速依賴自動化軟體解決方案來維持業務連續性。

市場挑戰

先進製藥生產軟體的實施需要大量資金投入，這成為限制市場成長的主要阻礙因素。整合諸如生產執行系統 (MES) 等數位化系統，需要對軟體授權、基礎設施升級以及資源彙整密集的驗證通訊協定進行大量投資，以滿足監管標準。如此高的財務門檻構成了准入壁壘，尤其對於利潤率低、難以承擔如此巨額初始成本的中小型契約製造而言更是如此。

因此，這種經濟壓力正在減緩數位技術在整個產業的普及，主要限制了大型、資金雄厚的公司快速採用這些技術。產業調查顯示，這些財務障礙的影響顯而易見。包裝與加工技術協會 (PMMI) 的報告指出，到 2024 年，48% 的製藥公司將把成本列為採用自動化和連網設備的主要障礙。由於製造商為了保持流動性而推遲投資，這抑制了對製造軟體解決方案的整體需求，直接阻礙了市場的成長軌跡，儘管這些系統顯然能夠提高營運效率。

市場趨勢

將人工智慧 (AI) 整合到預測性流程最佳化中，正從根本上推動產業發展，使其超越基礎自動化，邁向自主、自糾正的生產系統。製造商正積極採用生成式人工智慧和機器學習演算法，透過分析歷史批次資料、即時調整程式參數並最大限度地減少廢棄物，主動預測品質偏差。這種轉變的重點在於提高產品品質和產量比率，而不僅僅是提高操作速度，它利用深度學習來識別傳統分析方法無法捕捉到的生物反應器性能中的複雜模式。根據羅克韋爾自動化公司於 2025 年 6 月發布的《第十份年度智慧製造報告：生命科學版》，目前 53% 的生命科學製造商正在專門利用人工智慧來提高產品品質並減少批次不合格率，這標誌著人工智慧正從實驗性試點轉向核心營運基礎設施。

同時，資訊科技 (IT) 與操作技術(OT) 的整合（IT/OT 融合）正在打破現場控制系統與企業級資料架構之間的傳統障礙。這一趨勢的特徵是在整個製造生命週期中實現統一的資料管治，從而實現製造執行系統 (MES) 和業務線計劃 (ERP) 平台之間的無縫互通性。透過整合這些領域，企業正在建立一個全面的數位化生態系統，確保數據完整性，並加速從實驗室到供應鏈的決策過程。根據靜脈注射藥物協會 (PDA) 2025 年 9 月更新的《數據管治和人工智慧對製藥生產的影響》報告，該行業的數位成熟度評分達到 5 分中的 3.5 分，這反映出在連接 IT 和 OT 基礎設施以應對工業數據生成量指數級成長方面取得了顯著成效。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球製藥製造軟體市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按軟體類型分類（製造執行系統 (MES)、企業資源計劃 (ERP) 系統、實驗室資訊管理系統 (LIMS)、品管系統 (QMS)、流程分析技術 (PAT) 系統）
    • 依部署模式（本機部署、雲端部署）
    • 按最終用戶分類（製藥公司、契約製造組織 (CMO)、生物技術公司、研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美製藥生產軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲製藥製造軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區製藥生產軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲製藥製造軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲製藥製造軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球製藥生產軟體市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • BatchMaster Software, Inc
  • MasterControl Solutions, Inc
  • Sage Group plc
  • Oracle Corporation
  • Aquilon Software
  • CompuTec SA
  • Datacor, Inc.
  • Deskera US Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24339

The Global Pharmaceutical Manufacturing Software Market is projected to expand from USD 3.25 Billion in 2025 to USD 5.14 Billion by 2031, registering a CAGR of 7.94%. This sector comprises digital systems engineered to manage, oversee, and enhance drug production workflows while guaranteeing rigorous compliance with regulatory requirements. Key components of this market include Manufacturing Execution Systems and Enterprise Quality Management Systems, which facilitate the digitization of batch records and streamline operations to uphold Good Manufacturing Practices, ultimately offering manufacturers essential real-time operational insight and data integrity throughout the product lifecycle.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.25 Billion
Market Size 2031USD 5.14 Billion
CAGR 2026-20317.94%
Fastest Growing SegmentManufacturing Execution Systems (MES)
Largest MarketNorth America

Market growth is largely fueled by the strict need for regulatory adherence and the operational requirement to reduce production delays through superior process management. As companies strive to remove human error and secure consistent output, the dependence on automated monitoring solutions has grown significantly. According to PMMI, The Association for Packaging and Processing Technologies, 83% of pharmaceutical manufacturers in 2024 listed reliability and repeatability as primary operational goals, a need directly addressed by advanced automation software. Nevertheless, the high capital costs associated with implementation and the stringent validation procedures required for new systems pose considerable obstacles that may limit adoption among smaller manufacturing entities.

Market Driver

The rapid adoption of Pharma 4.0 and smart manufacturing technologies is fundamentally reshaping the market as companies integrate cyber-physical systems to enhance productivity. This digital evolution allows facilities to leverage Internet of Things sensors and advanced analytics, creating interconnected ecosystems that optimize batch release times and reduce downtime. Manufacturers are increasingly moving away from isolated legacy systems toward unified platforms that support predictive maintenance and autonomous decision-making. According to Rockwell Automation, March 2024, in the '9th Annual State of Smart Manufacturing Report: Life Sciences Edition', 96% of life sciences manufacturers reported that they are using or evaluating smart manufacturing technologies to improve their agility and competitive posture.

Concurrently, the rising demand for real-time quality assurance and end-to-end supply chain traceability is compelling manufacturers to upgrade their software infrastructure. Regulatory bodies are enforcing stricter serialization mandates to combat counterfeit drugs, necessitating robust platforms that ensure data integrity and transparency from raw material sourcing to final delivery. According to Zebra Technologies, June 2024, in the '2024 Pharmaceutical Supply Chain Vision Study', 76% of patients surveyed indicated that they expect pharmaceutical manufacturers to use advanced technology to ensure medication safety and verify provenance. To support these technological demands amidst labor shortages, manufacturers are increasing their digital budgets; according to the National Association of Manufacturers, March 2024, in the 'Manufacturers' Outlook Survey First Quarter 2024', 65% of industrial leaders cited the inability to attract and retain a quality workforce as a primary business challenge, accelerating the reliance on automated software solutions to maintain operational continuity.

Market Challenge

The substantial capital expenditure required for implementing advanced pharmaceutical manufacturing software acts as a major restraint on market growth. Integrating digital systems like Manufacturing Execution Systems requires heavy investment in software licensing, infrastructure upgrades, and the resource-intensive validation protocols necessary to meet regulatory standards. This high financial threshold creates a substantial barrier to entry, particularly for small and medium-sized contract manufacturing organizations that operate on thinner profit margins and cannot easily absorb such significant upfront costs.

Consequently, this economic pressure slows the broader diffusion of digital technologies across the industry, confining rapid adoption largely to well-capitalized tier-one companies. The impact of this financial hurdle is evident in industry surveys; according to the Association for Packaging and Processing Technologies (PMMI), in 2024, 48% of pharmaceutical manufacturers identified cost as a primary barrier to the adoption of automation and connected machinery. As manufacturers delay investment to preserve liquidity, the aggregate demand for manufacturing software solutions is dampened, directly hampering the market's trajectory despite the clear operational efficiencies these systems offer.

Market Trends

The Integration of Artificial Intelligence for Predictive Process Optimization is fundamentally advancing the sector by moving beyond basic automation to autonomous, self-correcting production systems. Manufacturers are increasingly deploying generative AI and machine learning algorithms to analyze historical batch data, predicting quality deviations before they occur and adjusting process parameters in real-time to minimize waste. This shift focuses heavily on enhancing product quality and yield rather than just operational speed, utilizing deep learning to identify complex patterns in bioreactor performance that traditional analytics miss. According to Rockwell Automation, June 2025, in the '10th Annual State of Smart Manufacturing Report: Life Sciences Edition', 53% of life sciences manufacturers are now utilizing artificial intelligence specifically to improve product quality and reduce batch failures, signaling a transition from experimental pilots to core operational reliance.

Concurrently, the Convergence of Information Technology and Operational Technology (IT/OT) is dissolving the traditional silos between shop floor control systems and enterprise-level data architectures. This trend is characterized by the unified governance of data across the manufacturing lifecycle, enabling seamless interoperability between Manufacturing Execution Systems (MES) and Enterprise Resource Planning (ERP) platforms. By integrating these domains, companies are achieving a holistic digital ecosystem that ensures data integrity and accelerates decision-making from the laboratory to the supply chain. According to the Parenteral Drug Association (PDA), September 2025, in the 'Data Governance and AI's Impact on Drug Manufacturing' update, the industry's digital maturity score has reached 3.5 out of 5, reflecting a measurable success in bridging IT and OT infrastructures to manage the surge in industrial data generation.

Key Market Players

  • BatchMaster Software, Inc
  • MasterControl Solutions, Inc
  • Sage Group plc
  • Oracle Corporation
  • Aquilon Software
  • CompuTec S.A.
  • Datacor, Inc.
  • Deskera US Inc

Report Scope

In this report, the Global Pharmaceutical Manufacturing Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Manufacturing Software Market, By Software Type

  • Manufacturing Execution Systems (MES)
  • Enterprise Resource Planning (ERP) Systems
  • Laboratory Information Management Systems (LIMS)
  • Quality Management Systems (QMS)
  • Process Analytical Technology (PAT) Systems

Pharmaceutical Manufacturing Software Market, By Deployment Mode

  • On-Premises
  • Cloud-Based

Pharmaceutical Manufacturing Software Market, By End User

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Biotechnology Companies
  • Research Organizations

Pharmaceutical Manufacturing Software Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Manufacturing Software Market.

Available Customizations:

Global Pharmaceutical Manufacturing Software Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Manufacturing Software Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Software Type (Manufacturing Execution Systems (MES), Enterprise Resource Planning (ERP) Systems, Laboratory Information Management Systems (LIMS), Quality Management Systems (QMS), Process Analytical Technology (PAT) Systems)
    • 5.2.2. By Deployment Mode (On-Premises, Cloud-Based)
    • 5.2.3. By End User (Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Biotechnology Companies, Research Organizations)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Manufacturing Software Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Software Type
    • 6.2.2. By Deployment Mode
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Manufacturing Software Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Software Type
        • 6.3.1.2.2. By Deployment Mode
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pharmaceutical Manufacturing Software Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Software Type
        • 6.3.2.2.2. By Deployment Mode
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pharmaceutical Manufacturing Software Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Software Type
        • 6.3.3.2.2. By Deployment Mode
        • 6.3.3.2.3. By End User

7. Europe Pharmaceutical Manufacturing Software Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Software Type
    • 7.2.2. By Deployment Mode
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Manufacturing Software Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Software Type
        • 7.3.1.2.2. By Deployment Mode
        • 7.3.1.2.3. By End User
    • 7.3.2. France Pharmaceutical Manufacturing Software Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Software Type
        • 7.3.2.2.2. By Deployment Mode
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pharmaceutical Manufacturing Software Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Software Type
        • 7.3.3.2.2. By Deployment Mode
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pharmaceutical Manufacturing Software Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Software Type
        • 7.3.4.2.2. By Deployment Mode
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pharmaceutical Manufacturing Software Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Software Type
        • 7.3.5.2.2. By Deployment Mode
        • 7.3.5.2.3. By End User

8. Asia Pacific Pharmaceutical Manufacturing Software Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Software Type
    • 8.2.2. By Deployment Mode
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Manufacturing Software Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Software Type
        • 8.3.1.2.2. By Deployment Mode
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pharmaceutical Manufacturing Software Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Software Type
        • 8.3.2.2.2. By Deployment Mode
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pharmaceutical Manufacturing Software Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Software Type
        • 8.3.3.2.2. By Deployment Mode
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pharmaceutical Manufacturing Software Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Software Type
        • 8.3.4.2.2. By Deployment Mode
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pharmaceutical Manufacturing Software Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Software Type
        • 8.3.5.2.2. By Deployment Mode
        • 8.3.5.2.3. By End User

9. Middle East & Africa Pharmaceutical Manufacturing Software Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Software Type
    • 9.2.2. By Deployment Mode
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Manufacturing Software Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Software Type
        • 9.3.1.2.2. By Deployment Mode
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Pharmaceutical Manufacturing Software Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Software Type
        • 9.3.2.2.2. By Deployment Mode
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Pharmaceutical Manufacturing Software Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Software Type
        • 9.3.3.2.2. By Deployment Mode
        • 9.3.3.2.3. By End User

10. South America Pharmaceutical Manufacturing Software Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Software Type
    • 10.2.2. By Deployment Mode
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Manufacturing Software Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Software Type
        • 10.3.1.2.2. By Deployment Mode
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Pharmaceutical Manufacturing Software Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Software Type
        • 10.3.2.2.2. By Deployment Mode
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Pharmaceutical Manufacturing Software Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Software Type
        • 10.3.3.2.2. By Deployment Mode
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Manufacturing Software Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. BatchMaster Software, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. MasterControl Solutions, Inc
  • 15.3. Sage Group plc
  • 15.4. Oracle Corporation
  • 15.5. Aquilon Software
  • 15.6. CompuTec S.A.
  • 15.7. Datacor, Inc.
  • 15.8. Deskera US Inc

16. Strategic Recommendations

17. About Us & Disclaimer